Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα

Journal of Clinical Investigation

Volumn 124, Issue 8, 2014, Pages 3501-3513

  Lu, Yan ^a   Liu, Xing ^a   Jiao, Yang ^a   Xiong, Xuelian ^a   Wang, E ^a   Wang, Xiaolin ^a   Zhang, Zhijian ^a   Zhang, Huijie ^a   Pan, Lingling ^a   Guan, Youfei ^b   Cai, Dongsheng ^c   Ning, Guang ^a,d   Li, Xiaoying ^a,d,e  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shenzhen University   (China)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d E Institutes of Shanghai Universities   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6BETA4 INTEGRIN; NEUTRALIZING ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSCRIPTION FACTOR RUNX2; CELL ADHESION MOLECULE; MESSENGER RNA; POSTN PROTEIN, HUMAN; POSTN PROTEIN, MOUSE; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RORA PROTEIN, HUMAN; RORA PROTEIN, MOUSE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID OXIDATION; FATTY LIVER; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSACTIVATION; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; COMPLICATION; CROSS-SECTIONAL STUDY; DEFICIENCY; FEMALE; GENETICS; HEPG2 CELL LINE; KNOCKOUT MOUSE; LIVER; MALE; METABOLISM; MOUSE MUTANT; OBESITY; PROMOTER REGION; UPREGULATION;

ANIMALS; CELL ADHESION MOLECULES; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; FATTY LIVER; FEMALE; HEP G2 CELLS; HUMANS; HYPERTRIGLYCERIDEMIA; INTEGRIN ALPHA6BETA4; LIVER; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; MODELS, BIOLOGICAL; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 1; OBESITY; PPAR ALPHA; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRIGLYCERIDES; UP-REGULATION;

EID: 84905492812     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74438     Document Type: Article

References (72)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-1231.
2. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332(6037):1519-1523.
3. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2011;8(1):35-44.
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330-344.
5. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679-689.
6. Rios H, et al. Periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol. 2005;25(24):11131-11144.
7. Merle B, Garnero P. The multiple facets of periostin in bone metabolism. Osteoporos Int. 2012;23(4):1199-1212.
8. Bao S, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004;5(4):329-339.
9. Kudo Y, et al. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res. 2006;66(14):6928-6935.
10. Michaylira CZ, et al. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumorinvasive signature in esophageal cancer. Cancer Res. 2010;70(13):5281-5292.
11. Malanchi I, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2011;481(7379):85-89.
12. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci. 2009;66(14):2219-2230.
13. Lu Y, et al. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut. 2014;63(1):170-178.
14. Clee SM, Attie AD. The genetic landscape of type 2 diabetes in mice. Endocr Rev. 2007;28(1):48-83.
15. Zhang HJ, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013;59(3):557-562.
16. Zhang H, et al. Glucose-mediated repression of menin promotes pancreatic β-cell proliferation. Endocrinology. 2012;153(2):602-611.
17. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 2006;4(2):107-110.
18. Benhamed F, et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest. 2012;122(6):2176-2194.
19. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118(3):829-838.
20. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):852-858.
21. Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol. 2010;6(8):454-463.
22. Bennett BL, et al. SP600125, an anthrapyrazolone inhibitor of Jun. N-terminal kinase. Proc Natl Acad Sci U S A. 2001;98(24):13681-13686.
23. Berrier AL, Martinez R, Bokoch GM, LaFlamme SE. The integrin beta tail is required and sufficient to regulate adhesion signaling to Rac1. J Cell Sci. 2002;115(pt 22):4285-4291.
24. Nodari A, et al. β1 Integrin activates Rac1 in Schwann cells to generate radial lamellae during axonal sorting and myelination. J Cell Biol. 2007;177(6):1063-1075.
25. Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet. 2003;12(11):1211-1221.
26. Sharma M, Urano F, Jaeschke A. Cdc42 and Rac1 are major contributors to the saturated fatty acidstimulated JNK pathway in hepatocytes. J Hepatol. 2012;56(1):192-198.
27. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA. 2004;101(20):7618-7623.
28. Pineda Torra I, Jamshidi Y, Flavell DM, Fruchart JC, Staels B. Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol. 2002;16(5):1013-1028.
29. Ma X, et al. Deletion of steroid receptor coactivator-3 gene ameliorates hepatic steatosis. J Hepatol. 2011;55(2):445-452.
30. Maglich JM, Lobe DC, Moore JT. The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J Lipid Res. 2009;50(3):439-445.
31. Kim EJ, et al. Retinoic acid receptor-related orphan receptor α-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis. Hepatology. 2012;55(5):1379-1388.
32. Ravnskjaer K, Boergesen M, Dalgaard LT, Mandrup S. Glucose-induced repression of PPARa gene expression in pancreatic beta-cells involves PP2A activation and AMPK inactivation. J Mol Endocrinol. 2006;36(2):289-299.
33. Boergesen M, Poulsen Ll, Schmidt SF, Frigerio F, Maechler P, Mandrup S. ChREBP mediates glucose repression of peroxisome proliferator-activated receptor a expression in pancreatic β-cells. J Biol Chem. 2011;286(15):13214-13225.
34. Utispan K. Periostin activates integrin a5β1 through a PI3K/AKT-dependent pathway in invasion of cholangiocarcinoma. Int J Oncol. 2012;41(3):1110-1118.
35. Ouyang G, Liu M, Ruan K, Song G, Mao Y, Bao S. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett. 2009;281(2):213-219.
36. Hirosumi J, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333-336.
37. Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab. 2010;21(12):707-713.
38. Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology. 2012;143(2):307-320.
39. Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A. 2006;103(44):16454- 16459.
40. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A. 2006;103(28):10741-10746.
41. Schattenberg JM, et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology. 2006;43(1):163-172.
42. Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja MJ. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology. 2009;49(1):87-96.
43. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116(3):571-580.
44. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferatoractivated receptor a mediates the adaptive response to fasting. J Clin Invest. 1999;103(11):1489-1498.
45. Li S, et al. Genome-wide coactivation analysis of PGC-1a identifies BAF60a as a regulator of hepatic lipid metabolism. Cell Metab. 2008;8(2):105-117.
46. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327-338.
47. Kulozik P, et al. Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia. Cell Metab. 2011;13(4):389-400.
48. Chen S, Li Y, Li S, Yu C. A Val227Ala substitution in the peroxisome proliferator activated receptor a (PPARa) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. J Gastroenterol Hepatol. 2008;23(9):1415-1418.
49. Yoneda M, et al. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2008;8:27.
50. Saudubray JM, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis. 1999;22(4):488-502.
51. Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res. 2011;52(4):593-617.
52. Kohjima M, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007;20(3):351-358.
53. Videla LA, Pettinelli P. Misregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity. PPAR Res. 2012;2012:107434.
54. Robitaille J, et al. Association between the PPARa-L162V polymorphism and components of the metabolic syndrome. J Hum Genet. 2004;49(9):482-489.
55. Flavell DM, et al. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes. 2005;54(2):582-586.
56. Sparsø T, et al. Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middleaged white people. Mol Genet Metab. 2007;90(2):205-209.
57. *3-Leiden. CETP mice. J Biol Chem. 2010;285(33):25168-25175.
58. Chan SM, et al. Activation of PPARa ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes. 2013;62(6):2095-2105.
59. Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol. 2013;5(9):470-478.
60. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet. 1999;353(9166):1802.
61. Athyros VG, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22(5):873-883.
62. Drosatos K, et al. Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferatoractivated receptor a expression and fatty acid oxidation and prevents lipopolysaccharideinduced heart dysfunction. J Biol Chem. 2011;286(42):36331-36339.
63. Lau P, Nixon SJ, Parton RG, Muscat GE. RORalpha regulates the expression of genes involved in lipid homeostasis in skeletal muscle cells: caveolin-3 and CPT-1 are direct targets of ROR. J Biol Chem. 2004;279(35):36828-36840.
64. Bengal E, et al. Functional antagonism between c-Jun. and MyoD proteins: a direct physical association. Cell. 1992;68(3):507-519.
65. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature. 1998;394(6696):909-913.
66. Xiong X, et al. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol. 2014;60(4):847-854.
67. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARa and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426-437.
68. Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93(11):4479-4485.
69. Li J, et al. Pancreatic-derived factor promotes lipogenesis in the mouse liver: role of the Forkhead box 1 signaling pathway. Hepatology. 2011;53(6):1906-1916.
70. Dushay J, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010;139(2):456-463.
71. Stefan N, Häring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013;9(3):144-152.
72. Yokoyama WM, et al. Production of monoclonal antibodies. Curr Protoc Immunol. 2013;102:Unit 2.5.